A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme

作者：Galore Haskel Gilli; Nemlich Yael; Greenberg Eyal; Ashkenazi Shira; Hakim Motti; Itzhaki Orit; Shoshani Noa; Shapira Fromer Ronnie; Ben Ami Eytan; Ofek Efrat; Anafi Liat; Besser Michal J; Schachter Jacob; Markel Gal^*

来源：Oncotarget, 2015, 6(30): 28999-29015.

DOI：10.18632/oncotarget.4905

• melanoma
• immune resistance
• microRNA
• ADAR1
• ICAM1

The blossom of immunotherapy in melanoma highlights the need to delineate mechanisms of immune resistance. Recently, we have demonstrated that the RNA editing protein, adenosine deaminase acting on RNA-1 (ADAR1) is down-regulated during metastatic transition of melanoma, which enhances melanoma cell proliferation and tumorigenicity. Here we investigate the role of ADAR1 in melanoma immune resistance.
Importantly, knockdown of ADAR1 in human melanoma cells induces resistance to tumor infiltrating lymphocytes in a cell contact-dependent mechanism. We show that ADAR1, in an editing-independent manner, regulates the biogenesis of miR-222 at the transcription level and thereby Intercellular Adhesion Molecule 1 (ICAM1) expression, which consequently affects melanoma immune resistance. ADAR1 thus has a novel, pivotal, role in cancer immune resistance. Corroborating with these results, the expression of miR-222 in melanoma tissue specimens was significantly higher in patients who had no clinical benefit from treatment with ipilimumab as compared to patients that responded clinically, suggesting that miR-222 could function as a biomarker for the prediction of response to ipilimumab.
These results provide not only novel insights on melanoma immune resistance, but also pave the way to the development of innovative personalized tools to enable optimal drug selection and treatment.

• 出版日期2015-10-6